Abstract
Importance Hidradenitis suppurativa (HS) has been associated with spondyloarthritis (SpA) and inflammatory bowel disease (IBD) and proposed as a potential manifestation of these conditions. However, the relative rarity of HS, combined with the diverse methodologies used in previous studies, leaves several uncertainties surrounding its epidemiology within this disease spectrum.
Objective To describe the prevalence and incidence of HS across pathologically related diseases within the spondyloarthritis (SpA) family, namely psoriasis, psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), uveitis, Crohn’s disease, and ulcerative colitis.
Design Cohort study conducted using data between January 2005 and January 2025.
Setting The study used data from electronic health records of over 135 million individuals across more than 100 healthcare organizations in North America.
Participants Six disease populations ranging from 46,928 to 191,605 individuals.
Exposures Populations of psoriasis, PsA, axial spondyloarthritis, uveitis, Crohn’s disease, and ulcerative colitis.
Main outcomes and measures Prevalence and incidence per 100,000 patient-years of HS.
Results The prevalence of HS was 0.4% in psoriasis and PsA, higher than axSpA (0.2%), Crohn’s disease (0.3%) or ulcerative colitis (0.2%). HS incidence was higher in psoriasis (124/100,000 patient-years) and PsA (119/100,000 patient-years) than other SpA-related disease (range 69 to 88/100,000 patient-years), with the exception of Crohn’s disease (177//100,000 patient-years).
Conclusions and Relevance This study highlights a significant epidemiological association between HS and SpA-related diseases, particularly psoriatic disease and Crohn’s disease. Clinicians providing care to these patient groups should consider enquiring about HS symptoms, although overall incidence rates are low. Further research is needed into the shared pathophysiology of HS and psoriatic disease.
Question What is the prevalence and incidence of hidradenitis suppurativa (HS) in conditions with shared immunopathology such as psoriatic disease, axial spondyloarthritis, uveitis, and inflammatory bowel disease?
Findings This cohort study found high prevalence and incidence of HS among individuals with psoriatic disease and confirmed previously reported high incidence in Crohn’s disease. Incidence rates of HS in other diseases of the spondyloarthritis family, such as axial spondyloarthritis, were lower.
Meaning Clinicians providing care for people with psoriatic disease should consider enquiring about HS symptoms, although overall incidence rates are low.
Competing Interest Statement
SSZ has received support from Alfasigma, Eli Lilly, Novartis and UCB for conference attendance and Honoria from Abbvie, Novartis and UCB for speaking at non-promotional educational events. UA has received honoraria from Eli Lilly, Procter & Gamble, Viatris, Grunenthal and Sanofi for educational meetings and funding for attendance to educational meetings from Daiichi Sankyo and Sanofi. UA has also received investigator-led funding by Procter & Gamble and is a council member of the Royal Society of Medicine's Vascular, Lipid & Metabolic Medicine Section. The other authors declare no conflicts of interest.
Funding Statement
SSZ is supported by a National Institute for Health and Care Research (NIHR) Clinical Lectureship and works in centres supported by Versus Arthritis (grant no. 21173, 21754 and 21755) and the NIHR Manchester Biomedical Research Centre (NIHR203308). The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Analyses are performed at individual HCOs with only aggregate results returned to the platform. Additional ethical approval was not required because this study used only de-identified data and did not involve the collection, use, or transmittal of identifiable data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from TriNetX, LLC but third-party restrictions apply to the availability of these data. The data were used under license for this study with restrictions that do not allow for the data to be redistributed or made publicly available. However, for accredited researchers, the TriNetX data is available for licensing at TriNetX, LLC. To gain access to the data in the TriNetX research network, a request can be made to TriNetX (trinetx.com), but costs may be incurred, a data sharing agreement would be necessary, and no patient identifiable information can be obtained.
